Background
Methods
Patients and tumors
Immunohistochemistry
DNA extraction
Array CGH
Oligonucleotide microarray platform
Analyses
Availability of data
Hierarchical clustering
Genomic instability of the tumors
Results
Tumor ID | Histological type | Tumor grade | IHC | Mutation detected | Family History | ||||
---|---|---|---|---|---|---|---|---|---|
ER | PR | HER2 | BRCA1 | BRCA1 | BRCA2 | ||||
T6 | IDC | III | - | - | - | - | 4 breast, 1 esophageal cancer | ||
T10 | IDC | III | - | - | - | - | 2 breast, 1 prostate cancer | ||
T11 | IDC | III | - | - | - | - | 1 breast bilateral with ovarian cancer | ||
T12 | IDC | II | - | + | - | - | 2 breast OR 1 breast, 1 ovarian, 1 stomach cancer | ||
T17 | IDC | III | - | - | - | - | 2 breast, 1 uterine, 1 testicular cancer | ||
T20 | LCIS | _ | - | - | 1+ | - | 3 breast, 1 stomach cancer | ||
T24 | IDC | II | - | - | - | - |
YES
| 1 bilateral and 2 breast, 1 gallbladder cancer, 1 melanoma | |
T39 | IDC | III | - | - | - | - | 1 bilateral and 3 breast cancer, 1 uterine, 1 stomach cancer | ||
T41 | IDC | III | - | - | - | - | 4 breast, 2 stomach,1 prostate cancer | ||
T42 | IDC | III | - | - | - | - | 4 breast, 2 stomach,1 prostate cancer | ||
T43 | IDC | III | - | - | - | - | 4 breast, 2 stomach,1 prostate cancer | ||
T45 | IDC | II | - | + | - | - | 1 bilateral breast, 4 breast, 1 testicular cancer | ||
T25 | IDC | III | + | + | - | - |
YES
| 1 bilateral and 2 breast, 1 gallbladder cancer, 1 melanoma | |
T1 | IDC | III | + | - | 1+ | - | 5 breast, 1 stomach, 1 gallbladder, 1 other cancer | ||
T3 | IDC | III | + | + | - | - | 2 breast, 1 uterine, 1 gallbladder, 1 esophageal cancer, 2 other cancer | ||
T26 | IDC | III | + | + | - | - | 6 breast, 1 stomach cancer, 1 leukemia | ||
T29 | IDC | II | + | + | 1+ | - | 5 breast, 1 liver, 2 stomach cancer | ||
T32 | IDC | I | + | + | - | - | 3 breast, 1 prostate, 1 uterine cancer | ||
T35 | IDC | I | + | + | - | - | 5 breast, 1 bilateral breast, 1 stomach, 1 pancreatic cancer | ||
T36 | IDC | I | + | + | - | - | 3 breast cancer | ||
T37 | IDC | II | + | + | - | - | 4 breast (1 bilateral), 1 testicular, 1 other cancer | ||
T9 | LCIS | _ | + | + | 3+ | - | 4 breast (1breast/colon), 3 stomach, 2 prostate, 1 pancreatic cancer | ||
T15 | IDC | II | + | + | 2+ | - | 3 breast cancer, one in a male | ||
T21 | ILC | _ | + | + | 2+ | - | 3 breast, 1 stomach, 1 other cancer | ||
T4 | IDC | I | - | + | - | + | 3 breast cancer | ||
T5 | IDC | III | - | - | - | + |
YES
| 2 breast, 1 stomach cancer, 1 leukemia | |
T16 | IDC | I | - | + | - | + | 2 breast, 1 uterine, 1 stomach cancer | ||
T23 | IDC | III | - | - | - | + | 1 breast, 1 prostate OR 1 breast, 1 stomach, 1 other cancer | ||
T19 | LCIS | _ | - | + | 2+ | + | 3 breast, 1 stomach cancer | ||
T46 | IDC | III | - | - | 3+ | + | 1 bilateral and 1 breast cancer | ||
T44 | DCIS | _ | + | + | - | + |
YES
| 1 bilateral and 3 breast cancer, 1 ovarian cancer, 1 stomach, 1 other cancer | |
T49 | IDC | II | + | + | - | + |
YES
| 1 bilateral breast, 1 uterine cancer(abuela paterna) | |
T2 | DCIS | _ | + | + | - | + | 2 breast, 1 liver cancer | ||
T8 | ILC | _ | + | - | - | + | 1 bilateral breast cancer | ||
T13 | DCIS | _ | + | + | - | + | 3 breast, 1 uterine, 2 stomach cancer | ||
T22 | IDC | II | + | + | - | + | 2 breast, 2 ovarian, 1 lung cancer, 1 lymphoma | ||
T28 | DCIS | _ | + | + | 1+ | + | 3 breast cancer, 1 esophageal cancer | ||
T30 | ILC | _ | + | + | 1+ | + | 3 breast, 1 lymphoma | ||
T31 | IDC | I | + | + | - | + | 3 breast, 1 prostate, 1 uterine cancer | ||
T33 | IDC | III | + | + | - | + | 5 breast, 1 bilateral breast, 1 stomach, 1 pancreatic cancer | ||
T34 | IDC | II | + | + | - | + | 5 breast, 1 bilateral breast, 1 stomach, 1 pancreatic cancer | ||
T38 | LCIS | _ | + | + | - | + | 4 breast (1 bilateral), 1 testicular, 1 other cancer | ||
T47 | IDC | II | + | + | - | + | 2 breast, 1 prostate OR 2 breast, 1 stomach cancer | ||
T48 | IDC | III | + | - | - | + | 3 breast cancer | ||
T14 | DCIS | _ | + | + | 2+ | + | 5 breast cancer | ||
T51 | IDC | II | + | + | ND | ND |
YES
| 2 breast, 1 stomach cancer, 1 colon cancer, 1 myeloma | |
T50 | IDC | III | + | - | 1+ | ND |
YES
| 2 breast, 1 stomach cancer |
Genomic losses and gains in BRCAX breast cancer tumors
Chromosome | CytoBand | Start | Stop | Size bp | Percentage of BRCAX tumors (N = 40) | Candidate tumor suppressor genes | Other genes |
---|---|---|---|---|---|---|---|
1 | p31.1 | 78765816 | 79106841 | 341,025 | 12.5 | PTGFR, IFI44L, IFI44 | |
q21.2
|
148392365
|
148504936
|
112,571
|
22.5
|
PLEKHO1, APH1A
|
ANP32E, CA14
| |
q24.2 | 167969938 | 168079511 | 109,573 | 12.5 | C1orf156, C1orf112 | ||
3 | q25.1 | 152529936 | 152650652 | 120,716 | 12.5 | MED12L,P2RY13, P2RY12, IGSF10 | |
6 | p21.32 | 32897974 | 32905723 | 7749 | 15.0 | TAP2 | |
p21.32 | 32918832 | 32929682 | 10,850 | 17.5 | PSMB8 | TAP1 | |
p21.32 | 32932575 | 33057062 | 124,487 | 15.0 | HLA-DMB | PSMB9, BRD2 | |
p22.1
|
27200902
|
27210109
|
9207
|
20.0
|
HIST1H2BJ, HIST1H2AG
| ||
7 | q34 | 141051502 | 141137338 | 85,836 | 17.5 | SSBP1 | WEE2, TAS2R3, TAS2R4, TAS2R5 |
9 | q32 | 116094655 | 116176804 | 82,149 | 15.0 | COL27A1, ORM1, ORM2, AKNA | |
11 | q23.3 | 114614479 | 116165823 | 1,551,344 | 15.0 | CADM1 | BUD13, ZPR1, APOA5 |
12 | q13.2 | 54429832 | 54500555 | 70,723 | 12.5 | GDF11, CIP29, ORMDL2 | |
13 | q21.1 | 52406170 | 52944596 | 538,426 | 12.5 | OLFM4 | |
14 | q11.2 | 22424322 | 22467920 | 43,598 | 15.0 | REM2, RBM23, PRMT5 | |
15 | q11.2 | 20477397 | 20599137 | 121,740 | 15.0 | CYFIP1 | NIPA2, NIPA1 |
16 | q12.1 | 50773858 | 51032886 | 259,028 | 15.0 | TOX3 | |
17 |
q25.1
|
68713135
|
68845671
|
132,536
|
20.0
|
COG1, FAM104A, C17orf80, CDC42EP4, SDK2
| |
20 |
q12
|
39100100
|
39142168
|
42,068
|
22.5
|
TOP1
| |
q12 | 39201874 | 39331155 | 129,281 | 12.5 | PLCG1, ZHX3 | ||
22 | q11.21 | 19683237 | 19692296 | 9059 | 12.5 | LZTR1, THAP7 |
Chromosome | CytoBand | Start | Stop | Size bp | Percentage of BRCAX tumors (N = 40) | Candidate oncogenes | Other genes |
---|---|---|---|---|---|---|---|
1 |
q21.1
|
143706304
|
143905470
|
199,166
|
15.0
|
PDE4DIP
|
SEC22B
|
q21.1 | 144219515 | 144279910 | 60,395 | 12.5 | RBM8A | GNRHR2, PEX11B, ITGA10, ANKRD35 | |
q21.2 | 148240535 | 148367347 | 126,812 | 12.5 | OTUD7B | VPS45 | |
q21.2
|
148392365
|
148504936
|
112,571
|
17.5
|
PLEKHO1, APH1A, ANP32E, CA14
| ||
q21.2
|
148519890
|
148564234
|
44,344
|
15.0
|
C1orf54, C1orf51, MRPS21, PRPF3
| ||
q32.1 | 201456918 | 201966787 | 509,869 | 12.5 | BTG2 | CHIT1, FMOD, ATP2B4 | |
q32.1 | 202269067 | 202358437 | 89,370 | 12.5 | C1orf157, SOX13 | ||
q32.1
|
205037481
|
205260296
|
222,815
|
15.0
|
IL19, IL20, FAIM3
|
IL24, PIGR, FCAMR, C1orf116
| |
q32.2 | 205762617 | 206263053 | 500,436 | 12.5 | CD46, PLXNA2 | CR1, CR1L, CD34 | |
q32.2 | 207826895 | 208566054 | 739,159 | 12.5 | TRAF3IP3,LAMB3 | G0S2, HSD11B1, C1orf74, IRF6, C1orf107, SYT14, SERTAD4 | |
q41 | 213425725 | 213768607 | 342,882 | 12.5 | KCNK2 | ||
q42.12 | 223406336 | 224419278 | 1,012,942 | 12.5 | ENAH, LBR | DNAH14, SRP9, EPHX1, TMEM63A, LEFTY1, PYCR2, LEFTY2, C1orf55, H3F3A, ACBD3 | |
q42.13 | 225961050 | 226071970 | 110,920 | 12.5 | JMJD4, SNAP47, MPN2 | ||
6 | p21.33 | 31663820 | 31905687 | 241,867 | 12.5 | CLIC1, CSNK2B | LST1, NCR3, AIF1, BAT2, BAT3, APOM, BAT4, C6orf47, LY6G5B, LY6G5C, BAT5, LY6G6F, LY6G6E, LY6G6D, LY6G6C, DDAH2, MSH5, C6orf27, VARS, LSM2, HSPA1A, HSPA1B |
8 | q22.1 | 98923270 | 99014727 | 91,457 | 12.5 | LAPTM4B | MATN2 |
q22.3 | 104310836 | 104453937 | 143,101 | 12.5 | FZD6, CTHRC1 | BAALC | |
q23.1 | 107173263 | 107833235 | 659,972 | 12.5 | OXR1 | ||
q24.13 | 124926272 | 125341753 | 415,481 | 12.5 | FER1L6 | ||
q24.21 | 130632541 | 130857683 | 225,142 | 12.5 | GSDMC | ||
12 | q13.2 | 54405492 | 54500555 | 95,063 | 12.5 | CIP29 | CD63, GDF11, ORMDL2 |
17 | q12 | 34260921 | 34473439 | 212,518 | 12.5 | RPL23, PLXDC1, LASP1 | FBXO47 |
19 | q13.33 | 55918797 | 56055048 | 136,251 | 12.5 | KLK15, KLK3 | CLEC11A, GPR32, ACPT, C19orf48, KLK1 |
q13.42 | 60568830 | 60853735 | 284,905 | 12.5 | IL11, UBE2S | TMEM190, RPL28, ZNF579, FIZ1, ZNF524, ZNF580, ZNF581, CCDC106 | |
20 |
q12
|
39100100
|
39358266
|
258,166
|
15.0
|
PLCG1, TOP1
|
PRO0628, ZHX3
|
Specific genomic alterations in hereditary tumors from BRCA1 and BRCA2 mutation carriers
BRCA2 mutated tumors | BRCA1 mutated tumors | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Mutation 1 | Mutation 2 | Mutation 3 | Mutation 4 | ||||||||
Chr region | Start | Stop | Size bp | Genes | T50 | T5 | T51 | T44 | T49 | T24 | T25 |
1q41 | 212228277 | 212570219 | 341942 | PROX1, SMYD2
| Loss | Loss | |||||
2p25.1 | 11198066 | 11682912 | 484846 | PQLC3, ROCK2, E2F6, GREB1
| Gain | Gain | |||||
2q33.1 | 197759971 | 197921182 | 161211 | ANKRD44 | Loss | Loss | |||||
2q33.2 | 203984291 | 204102868 | 118577 | ABI2, RAPH1
| Loss | Loss | Loss | ||||
4q32.3-4q33 | 167949877 | 170912917 | 2963040 | SPOCK3, ANXA10, DDX60, PALLD, CBR4, SH3RF1, NEK1, CLCN3 | Loss | Loss | |||||
4q34.1-4q34.2 | 175832063 | 176792165 | 960102 | GLRA3, ADAM29, GMP6A | Loss | Loss | |||||
7p13 | 43308108 | 44125072 | 816964 |
HECW1, STK17A, BLVRA, MRPS24, URG4, UDE2D4, DBNL, PGAM2, POLM, AEBP1, POLD2 | Loss | Loss | |||||
11q12.1 | 58254147 | 58647789 | 393642 | GLYAT, GLYATL2, GLYATL1 | Loss | Loss | |||||
17q21.2 | 38450905 | 38521318 | 70413 |
BRCA1
| Loss | Loss | Loss | ||||
17q23.2 | 57344164 | 57454012 | 109848 | INTS2, MED13 | Loss | Loss | |||||
19q13.11 | 40168316 | 40221937 | 53621 | GRAMD1A, SCN1B | Loss | Loss | |||||
20q13.12 | 44813919 | 45159168 | 345249 | EYA2 | Loss | Loss | Loss |
BRCA1 expression and genomic alterations in hereditary breast tumors
Clustering analysis revealed four major groups of hereditary tumors
Gene ontology enrichment
Tumor groups | Enriched Gene Ontologies |
---|---|
BRCA1/2 mutated
| Regulation of cytoskeleton organization, Negative regulation of mammary epithelial cell proliferation, Protein modification process, Apoptosis, Cell cycle regulation, RNA transcription and processing, DNA damage repair, DNA packaging |
BRCA1 not expressing
| Alpha aminoacid metabolic/biosynthetic processes, Protein citrullination and Citrulline metabolism, Proteolysis, Transcription, Chromosome segregation and chromatin organization, Apoptosis |
BRCA1 expressing
| No enrichment was found |
Blue cluster
| Antigen processing and presentation (13 GO Terms), Intracellular transport |
Yellow cluster
| Cytokine signaling, Collagen metabolic processes and Extracellular matrix organization |
Purple cluster
| Calcium-independent cell-cell adhesion |
Green cluster
| No enrichment was found |